Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Eun Joo | - |
dc.contributor.author | Kim, Moo Hyun | - |
dc.contributor.author | Kim, Young-Hak | - |
dc.contributor.author | Chang, Kiyuk | - |
dc.contributor.author | Choi, Dong-Ju | - |
dc.contributor.author | Kang, Woong Chol | - |
dc.contributor.author | Shin, Jinho | - |
dc.contributor.author | Kim, Seong Hwan | - |
dc.contributor.author | Lee, Namho | - |
dc.contributor.author | Son, Jang Won | - |
dc.contributor.author | Doh, Joon-Hyung | - |
dc.contributor.author | Kim, Woo-Shik | - |
dc.contributor.author | Hong, Soon Jun | - |
dc.contributor.author | Rhee, Moo-Yong | - |
dc.contributor.author | Ahn, Youngkeun | - |
dc.contributor.author | Lim, Sang-Wook | - |
dc.contributor.author | Hong, Seung Pyo | - |
dc.contributor.author | Choi, So-Yeon | - |
dc.contributor.author | Hyon, Min Su | - |
dc.contributor.author | Hwang, Jin-Yong | - |
dc.contributor.author | Kwon, Kihwan | - |
dc.contributor.author | Cha, Kwang Soo | - |
dc.contributor.author | Ihm, Sang-Hyun | - |
dc.contributor.author | Lee, Jae-Hwan | - |
dc.contributor.author | Yoo, Byung-Su | - |
dc.contributor.author | Kim, Hyo-Soo | - |
dc.date.accessioned | 2023-12-14T06:31:51Z | - |
dc.date.available | 2023-12-14T06:31:51Z | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 1524-6175 | - |
dc.identifier.issn | 1751-7176 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25593 | - |
dc.description.abstract | The authors evaluated the efficacy, safety, and characteristics of patients who respond well to standard dose triple combination therapy including chlorthalidone 25 mg with telmisartan 80 mg plus amlodipine 5 mg in hypertensive patients. This is a multicenter, double-blind, active-controlled, phase 3, randomized trial. Patients are randomized to triple combination (telmisartan 40 mg/amlodipine 5 mg/chlorthalidone 12.5 mg, TEL/AML/CHTD group) or dual combination (telmisartan 40 mg/amlodipine 5 mg, TEL/AML group) treatment and then dose up titration to TEL 80/AML5/CHTD25mg and TEL80/AML5, respectively. The primary endpoint is the change of mean sitting systolic blood pressure (MSSBP) at week 8. A Target BP achievement rate, a response rate, and the safety endpoints are also evaluated. Total 374 patients (mean age = 60.9 +/- 10.7 years, male = 78.3%) were randomized to the study. The baseline MSSBPs/diastolic BPs were 149.9 +/- 12.2/88.5 +/- 10.4 mm Hg. After 8 weeks treatment, the change of MSSBPs at week 8 are -19.1 +/- 14.9 mm Hg (TEL/AML/CHTD) and -11.4 +/- 14.7 mm Hg (TEL/AML) (p < .0001). The achievement rates of target BP (53.8% vs. 37.8%, p = .0017) and responder rate (54.8% vs. 35.6%, p = .0001) at week 8 were significantly higher in TEL/AML/CHTD. There are no serious adverse event and no one discontinued medication due to adverse event. Among the TEL 80/AML5/CHTD25mg treatment group, patients of female or age >= 65 years old showed higher rate of target BP achievement than relatively young male. (61.4 vs. 46.8%, p = .042) Our study showed standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg is efficacious and safe in treatment of primary hypertension. Target BP achievement with triple therapy would be facilitated in female or old age. | - |
dc.format.extent | 11 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY | - |
dc.title | Efficacy and safety of standard dose triple combination of telmisartan 80 mg/amlodipine 5 mg/chlorthalidone 25 mg in primary hypertension: A randomized, double-blind, active-controlled, multicenter phase 3 trial | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/jch.14707 | - |
dc.identifier.scopusid | 2-s2.0-85168712738 | - |
dc.identifier.wosid | 001080168200001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL HYPERTENSION, v.25, no.9, pp 817 - 827 | - |
dc.citation.title | JOURNAL OF CLINICAL HYPERTENSION | - |
dc.citation.volume | 25 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 817 | - |
dc.citation.endPage | 827 | - |
dc.type.docType | Article; Early Access | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Peripheral Vascular Disease | - |
dc.subject.keywordPlus | LIPID-LOWERING TREATMENT | - |
dc.subject.keywordPlus | BLOOD-PRESSURE CONTROL | - |
dc.subject.keywordPlus | INDIAN PATIENTS | - |
dc.subject.keywordPlus | TASK-FORCE | - |
dc.subject.keywordPlus | CHLORTHALIDONE | - |
dc.subject.keywordPlus | HYDROCHLOROTHIAZIDE | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | MANAGEMENT | - |
dc.subject.keywordPlus | DIURETICS | - |
dc.subject.keywordPlus | AMLODIPINE | - |
dc.subject.keywordAuthor | amlodipine | - |
dc.subject.keywordAuthor | blood pressure | - |
dc.subject.keywordAuthor | chlorthalidone | - |
dc.subject.keywordAuthor | telmisartan | - |
dc.subject.keywordAuthor | triple combination | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.